A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer. 2019 Jun 13; 19(1):572.

View in: PubMed

subject areas

Adenocarcinoma
Adult
Aged
Aged, 80 and over
Androgen Receptor Antagonists
Antineoplastic Agents
Benzamides
Clinical Trials, Phase II as Topic
Double-Blind Method
Humans
Male
Middle Aged
Multicenter Studies as Topic
Neoplasm Metastasis
Neoplasm Recurrence, Local
Nitriles
Phenylthiohydantoin
Placebos
Prostatectomy
Prostatic Neoplasms, Castration-Resistant
Randomized Controlled Trials as Topic
Salvage Therapy
Survival Analysis
Treatment Outcome
Young Adult

authors with profiles

Stanley Liauw